by Randy E. Miller | May 30, 2024 | FDA, FOIA, Hedge Funds, News Media, Pharmaceuticals, Stock Market
FOIAengine: Requests Show FDA Still Under Pressure This week, we’re taking a closer look at the numerous Freedom of Information Act requests recently filed with the Food and Drug Administration concerning the problematic India pharmaceutical industry. As we noted in...
by Randy E. Miller | Mar 27, 2024 | FDA, FOIA, Hedge Funds, Law Firms, Litigation, Non-Profits, Pharmaceuticals, Politics, Short-Selling, Stock Market
FOIAengine: Conservative Activists, Law Firms, Non-Profits Signal Competing Agendas A review of the most recent Freedom of Information Act requests made to the Food and Drug Administration illustrates how political organizations, law firms, news media, and financial...
by John A. Jenkins | Mar 13, 2024 | FDA, FOIA, Law Firms, Non-Profits, Pharmaceuticals
FOIAengine Spotlights a Non-Profit Newsroom and Another Problem for the FDA The Food and Drug Administration was already under fire from Congress and others after hundreds of toddlers in 44 states were poisoned last year by lead-tainted pouches of apple puree and...
by Randy E. Miller | Feb 14, 2024 | FDA, FOIA, Hedge Funds, Litigation, Pharmaceuticals, Short-Selling, Stock Market
FOIAengine Breaks Down the Action Financial firms are continuing to monitor many of the pharmaceutical manufacturers we’ve reported on in recent months, including Krystal Biotech, Apellis Pharmaceuticals, Establishment Labs, Catalent and Astellas. That’s according to...
by Randy E. Miller | Jan 24, 2024 | FDA, FOIA, Law Firms, Litigation, Pharmaceuticals
In FOIAengine, a Law Firm’s Strategy Takes Shape When we tallied the hundreds of thousands of Freedom of Information Act requests filed with the federal government last year, one law firm stood out. According to PoliScio Analytics’ competitive-intelligence database...
by John A. Jenkins | Jan 3, 2024 | FDA, FOIA, Pharmaceuticals
FOIAengine Lines Up the Players in a Huge Patent Fight When the Food and Drug Administration announced three weeks ago the approval of two milestone treatments for sickle cell disease, the agency hailed the action as “an innovative advancement in the field of gene...
